TT-16

N/A

Report date: 2024/02/08 13:32:21

Base Information

Drug NameTT-16

Drug Alias NameHER2-CAR VSTs + Oncolytic & Helper Adenovirus(Tessa Therapeutics)HER2-specificCAR- TCAdVECTT-16

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Oncolytic virus

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsT lymphocytes stimulants +[4]

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTessa Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTessa Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A